$4.52
-0.30 (-6.22%)
Open$4.82
Previous Close$4.82
Day High$5.00
Day Low$4.52
52W High$415.80
52W Low$4.52
Volume—
Avg Volume8.6K
Market Cap2.35M
P/E Ratio—
EPS$-593.80
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+885.2% upside
Current
$4.52
$4.52
Target
$44.53
$44.53
$37.12
$44.53 avg
$63.68
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.28M | 1.20M | 1.36M |
| Net Income | 141.5K | 105.1K | 144.5K |
| Profit Margin | 11.1% | 8.8% | 10.6% |
| EBITDA | 291.4K | 241.4K | 275.9K |
| Free Cash Flow | 83.4K | 101.2K | 72.7K |
| Rev Growth | +11.3% | +13.4% | -9.5% |
| Debt/Equity | 0.31 | 0.28 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |